Proteína C activada (drotrecogina alfa activada) en el tratamiento de la sepsis grave

Levi, 2003, Infection and inflammation and the coagulation system, Cardiovasc Res, 60, 26, 10.1016/S0008-6363(02)00857-X Ten Cate, 2000, Pathophysiology of disseminated intravascular coagulation in sepsis, Crit Care Med, 28, S9, 10.1097/00003246-200009001-00003 Levi, 2001, Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation, Crit Care Med, 29, S90, 10.1097/00003246-200107001-00028 Vincent, 2002, Clinical trials of immunomodulatory therapies in severe sepsis and septic shock, Clin Infect Dis, 34, 1084, 10.1086/339549 Matthay, 2001, Severe sepsis. A new treatment with both anticoagulant and antiinflammatory properties, N Engl J Med, 344, 759, 10.1056/NEJM200103083441009 Murakami, 1997, Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production, Am J Physiol, 272, 197 Grinnell, 2001, Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis, Crit Care Med, 29, S53, 10.1097/00003246-200107001-00020 Grey, 1994, Selective inhibitory effects of the anticoagualant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-, or phorbol ester, J Inmunol, 153, 3664 Joyce, 2001, Gene expresion profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis, J Biol Chem, 276, 11199, 10.1074/jbc.C100017200 Bernard, 2001, and the Recombinant Human Activated Protein C Worldwide Evaluation in Sepsis (PROWESS) Study Group. Efficacy and safety of recombinat human activated protein C for severe sepsis, N Engl J Med, 344, 699, 10.1056/NEJM200103083441001 Barton, 2004, Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis, Pediatrics, 113, 7, 10.1542/peds.113.1.7 Levi, 2001, Pathogenesis and treatment of disseminated intravascular coagulation in the septic patient, J Crit Care, 16, 167, 10.1053/jcrc.2001.30666 Levi, 2001, Advances in the understanding of the pathogenetic pathways of disseminated intravascular coagulation result in more insight in the clinical picture and better management strategies, Semin Thromb Hemost, 27, 569, 10.1055/s-2001-18862 Nielsen, 1998, The effect of antithrombin on the systemic inflammatory response in disseminated intravascular coagulation, Blood Coagul Fibrinolysis, 9, S11 Hartman, 1998, Recombinant human activated protein C (rhAPC) improves coagulation abnormalities associated with severe sepsis, Intensive Care Med, 24, S77 Bernard, 2001, Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis, Crit Care Med, 29, 2051, 10.1097/00003246-200111000-00003 Derhaschnig, 2003, Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia, Blood, 102, 2093, 10.1182/blood-2003-02-0416 Dhainaut, 2003, and Recombinant Human Activated Protein C Worldwide Evaluation in Sepsis (PROWESS) Study Group. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial, Intensive Care Med, 29, 894, 10.1007/s00134-003-1731-1 Bernard, 2003, Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis, Crit Care, 7, 155, 10.1186/cc2167 Manns, 2002, An economic evaluation of activated protein C treatment for severe sepsis, N Engl J Med, 347, 993, 10.1056/NEJMsa020969 Angus, 2002, Drotrecogin alfa (activated). A viewpoint, Drugs, 62, 631, 10.2165/00003495-200262040-00008 Warren, 2002, Risks and benefits of activated Protein C treatment for severe sepsis, N Engl J Med, 347, 1027, 10.1056/NEJMsb020574